Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Lance Okeke

HIV/AIDS Medicine · Duke University

View

Dr. Raphael J. Landovitz

HIV/AIDS Medicine · UCLA

View

Dr. Aniruddha Hazra

HIV/AIDS Medicine · UCMC

View

Dr. Shital Patel

HIV/AIDS Medicine · BCM

View

Dr. Monica Gandhi

HIV/AIDS Medicine · UCSF

View

Dr. Ashwin Balagopal

HIV/AIDS Medicine · Johns Hopkins

View

Dr. Ofole Mgbako

HIV/AIDS Medicine · NYU Langone

View

Dr. Joshua Barocas

HIV/AIDS Medicine · CU Anschutz Medical Campus

View

Dr. Chris Beyrer

Global Health · Duke University

View

Dr. Keith Kaye

General ID · RU

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Penicillin allergy labels and antibiotic prescribing in carceral settings: expanding evidence from a statewide cohort.

    Jun 23, 2026DOI: 10.1017/ash.2026.10768LetterASHE

    Written by: Kap Sum FoongSamuel WilkRachel TamLindsay TaylorAlysse Wurcel

    Find these authors on Roon

    AW
    Dr. Alysse Wurcel
    HIV/AIDS Medicine · BMC

    To the Editor,

    Antimicrobial stewardship efforts have historically overlooked carceral settings, despite their disproportionate burden of infectious diseases and antimicrobial exposure.1 Antimicrobial resistance (AMR) is amplified in these environments due to structural vulnerabilities, limited antimicrobial stewardship infrastructure, and high baseline disease burden, yet prescribing practices remain understudied.2 We recently reported that among incarcerated individuals receiving antibiotics across four United States (U.S.) carceral systems, penicillin allergy labels (PALs) were associated with increased risk of receiving high-risk antibiotics for Clostridioides difficile infection (CDI).3 However, that analysis was restricted to individuals already exposed to antibiotics and could not estimate population-level PAL prevalence.To address this gap, we analyzed data from the Wisconsin Department of Corrections (DOC), leveraging a statewide census of 20,483 incarcerated individuals from 2021 to 2023. PALs were identified in 1,852 individuals (9.0%), which is comparable to prevalence estimates reported in the general U.S. population (10%).4 We then constructed a retrospective cohort including all individuals with a PAL and a randomly selected equal number of individuals without a PAL. Demographic characteristics and antibiotic prescriptions were collected, and antibiotics were categorized as high-risk or non–high-risk for CDI using National Healthcare Safety Network 2017 baseline criteria. Using conditional logistic regression, we evaluated associations between PAL, demographic characteristics (age, race, ethnicity), and antibiotic prescribing, including receipt of any antibiotic and high-risk antibiotics for CDI. A two-sided P value of <.05 was considered statistically significant. All statistical analyses were performed using SPSS, version 25 (IBM, Armonk, NY, USA). This study was reviewed by the Institutional Review Board of Tufts Medical Center and Wisconsin DOC and deemed low risk and exempt from full review.Demographic characteristics and antibiotic classes prescribed stratified by PAL status are summarized in Supplementary Table 1. Univariable analyses of factors associated with receipt of any antibiotics and receipt of high-risk antibiotics for CDI are presented in Supplementary Tables 2 and 3, respectively. Compared with incarcerated individuals without PALs, those with PALs were more likely to be prescribed any antibiotic (adjusted odds ratio [aOR], 1.208; 95% confidence interval [CI], 1.082–1.349) and had substantially higher odds of receiving high-risk antibiotics for CDI (aOR 6.318; 95% CI, 4.837–8.253) (Table 1). Compared with our prior multistate study,3 the strength of association between PALs and high-risk antibiotic use was notably greater, suggesting that PALs may exert a more pronounced influence on antibiotic selection within certain carceral systems.
    Table 1.Association of penicillin allergy labels with antibiotic prescribing outcomes in a Wisconsin DOC cohortTable 1 long description.VariableReceipt of any antibiotic (aOR, 95% CI)P valueReceipt of high-risk antibiotic for CDI (aOR, 95% CI)P valuePenicillin allergy label• NoReferenceReference• Yes1.208 (1.082–1.349)<.0016.318 (4.837–8.253)<.001Age• ≤ 25ReferenceReference• 26–351.121 (0.805–1.560).4992.008 (1.104–3.949).024• 36–451.119 (0.796–1.574).5161.980 (1.053–3.725).034• ≥461.116 (0.800–1.557).5202.609 (1.394–4.883).003Race• BlackReferenceReference• White1.007 (0.849–1.194).9380.898 (0.752–1.302).989• Other1.029 (0.753–1.406).8591.089 (0.662–1.793).737• Unknown0.786 (0.049–12.700).865Not estimableEthnicity• HispanicReferenceReference• Non-Hispanic1.337 (0.853–2.096).2051.111 (0.507–2.443).793• Unknown1.739 (1.121–2.696).0131.199 (0.560–2.569).640A table comparing demographic characteristics and antibiotic prescription rates among individuals with and without penicillin allergy labels.aOR, adjusted odds ratio; CDI, Clostridioides difficile infection; CI, confidence interval; DOC, Department of Corrections.*Adjusted for age, race, ethnicity, and penicillin allergy label.
    Association of penicillin allergy labels with antibiotic prescribing outcomes in a Wisconsin DOC cohort
    Table 1 long description.
    aOR, adjusted odds ratio; CDI, Clostridioides difficile infection; CI, confidence interval; DOC, Department of Corrections.
    Adjusted for age, race, ethnicity, and penicillin allergy label.
    This study adds several important insights beyond our prior work. First, it provides a population-level estimate of PAL prevalence in a carceral system, rather than limiting analysis to antibiotic-exposed individuals. Second, PALs were associated not only with antibiotic receipt but also with a substantially increased likelihood of receiving high-risk agents when antibiotics were prescribed, reinforcing their role in driving broader-spectrum antibiotic use and associated CDI risk.
    These findings are particularly relevant given the broader literature demonstrating that antimicrobial stewardship programs are rarely implemented in jails and prisons and that prescribing practices are highly variable across facilities.5 As most incarcerated individuals eventually return to the community, gaps in stewardship within carceral systems have direct implications for population-level AMR.6 In addition to structured allergy histories and risk stratification, direct oral challenge for low-risk patients may represent a feasible and resource-conscious stewardship intervention in carceral settings. Recent studies have demonstrated that direct oral challenge is safe, effective, less resource intensive than skin testing,7 and may be implemented outside of specialized allergy settings.8 Thus, direct oral challenge has the potential to be adopted across correctional healthcare systems with limited access to allergy specialists.
    Our findings should be interpreted in the context of several limitations. Data on underlying comorbidities and chronic medical conditions were not available in the data set. Additionally, individuals without a PAL were defined by the absence of a documented PAL in the electronic medical record, which may introduce ascertainment bias if individuals prescribed antibiotics underwent more detailed allergy assessment during clinical evaluation.
    In conclusion, our findings support incorporating penicillin allergy evaluation and delabeling into antimicrobial stewardship strategies in carceral settings. Targeted and resource-conscious interventions, such as structured allergy histories, risk stratification, and direct oral challenge, may represent high-yield opportunities to improve antibiotic prescribing and reduce downstream harms in this vulnerable population.

    Supporting information

    Foong et al. supplementary material
    AWDr. Alysse Wurcel

    Dr. Alysse Wurcel

    Infectious Disease · HIV & AIDS Medicine
    Boston Medical Center
    alysse